{"id":"sb213503-lot-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL5853519","moleculeType":null,"molecularWeight":"319.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCR3 is highly expressed on eosinophils and plays a central role in their migration to sites of inflammation. By antagonizing CCR3, SB213503 reduces eosinophil infiltration into airways and tissues, thereby decreasing inflammatory responses. This mechanism is particularly relevant in eosinophilic airway diseases where eosinophil accumulation drives pathology.","oneSentence":"SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:35.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (eosinophilic phenotype)"},{"name":"Allergic airway inflammation"}]},"trialDetails":[{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK Biologicals combined diphteria, tetanus, acellular pertussis and inactivated poliovirus lot 3 vaccine"],"phase":"phase_3","status":"active","brandName":"SB213503 lot 3","genericName":"SB213503 lot 3","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases. Used for Asthma (eosinophilic phenotype), Allergic airway inflammation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}